Filing Flows › AbbVie (ABBV) › Q3 2026 › vs Q3 2025
AbbVie (ABBV) Q3 2026 vs Q3 2025 (year over year)
AbbVie's revenue rose $1.6B (+10%) from $15.8B in Q3 2025 to $17.4B in Q3 2026. Operating margin 36.0% against 12.1% (+23.9 pts).
AbbVie, Q3 2026: revenue $17.4B (+10% year over year), operating margin 36.0%, net earnings $4.2B, operating cash flow $7.6B. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 36.0% | 12.1% | +23.9 pts |
| Net margin | 24.2% | 1.2% | +23.1 pts |
| Free cash flow margin | 42.0% | 42.1% | -0.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $17.4B | $15.8B | $1.6B | +10% |
| Operating profit | $6.3B | $1.9B | $4.4B | +229% |
| Costs & expenses | $11.1B | $13.9B | −$2.7B | -20% |
| Pre-tax earnings | $4.8B | $714M | $4.1B | +576% |
| Other expense, net | $1.4B | $1.2B | $248M | +21% |
| Cost of revenue | $4.3B | $5.3B | −$1.0B | -19% |
| Research & development | $2.6B | $2.3B | $248M | +11% |
| SG&A | $4.1B | $3.6B | $518M | +15% |
| Other operating costs | $198M | $2.7B | −$2.5B | -93% |
| Net earnings | $4.2B | $188M | $4.0B | 22× |
| Income tax | $609M | $526M | $83.0M | +16% |
| Depreciation & amortization | $1.9B | $2.1B | −$200M | -10% |
| Share-based compensation | $160M | $209M | −$49.0M | -23% |
| Working capital & other | $1.3B | $4.5B | −$3.2B | -71% |
| Operating cash flow | $7.6B | $7.0B | $582M | +8% |
| Free cash flow (OCF − capex) | $7.3B | $6.6B | $662M | +10% |
| Capital expenditures | $301M | $381M | −$80.0M | -21% |
Questions
How much did AbbVie's revenue grow year over year in Q3 2026?
AbbVie's revenue rose $1.6B (+10%) from $15.8B in Q3 2025 to $17.4B in Q3 2026. Operating margin 36.0% against 12.1% (+23.9 pts).